Sales expected to triple thanks to DefenCath - share with doubling potential, still under the radar of major investors

DefenCath revolutionizes the dialysis market: Successful launch and reimbursement programs secure market presence. Impressive sales potential: Sales growth of over 200% expected by 2025, driven by new partnerships. Optimistic forecasts: Analysts see a price target of up to $19, with a potential increase in value of 153%. CorMedix Inc (Nasdaq: CRMD) is increasingly attracting the attention of investors and analysts as the biopharmaceutical company is making promising progress with its innovative DefenCath product. Especially since...